Nordic Nanovector, Affibody to develop new radio-immunotherapies for multiple myeloma

Supported by a grant from Eurostars, the project will combine Affibody’s proprietary platforms with Nordic’s radioimmunotherapy technology.

Sweden’s Vinnova and the Norwegian Research Council have awarded around €1m for the project, which is designed to provide necessary documentation to commence GMP manufacturing of the Affibody-based RIT and subsequently start clinical trials.

Nordic Nanovector CEO Luigi Costa said: "The collaboration with Affibody will allow Nordic Nanovector to expand its product pipeline, while at the same time retaining full focus on the clinical development and commercialisation of our lead product candidate, Betalutin.

"This collaboration serves as an example of how the company intends to leverage its proprietary targeting technology to treat other haematological cancers in need of novel therapeutic approaches."

Following completion of the collaboration, Nordic Nanovector will be provided an opportunity to licence the global rights to the Affibody-based RIT.

Nordic Nanovector said that the development of an Affibody-based RIT treatment will be conducted in parallel with its lead product candidate Betalutin for non-Hodgkin Lymphoma treatment.